Why NII Holdings, Pacific Biosciences of California, and Cell Therapeutics Are Today's 3 Best Stocks

The S&P 500 dips on weaker economic data as NII Holdings, Pacific Biosciences of California, and Cell Therapeutics gallop higher by double-digits.

Jan 17, 2014 at 5:15PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

After roaring to new highs by mid-week, the broad-based S&P 500 (SNPINDEX:^GSPC) edged lower for a second straight day, after a trio of weak economic data and readings did the iconic index in.

Pushing the S&P 500 lower was a fairly significant drop in housing starts, which dipped 9.8% to a seasonally adjusted annual rate of 999,000 in December from 1.11 million in November. This figure of 999,000, in spite of the sizable drop, is still high relative to where we've been during the previous five years. It could, however, be a wake-up call that higher lending rates could stamp out rapid housing industry growth in the interim.

December's industrial production was also right in line with economists' expectations with an expansion of 0.3%, but this figure is down from 1% expansion in November. Similar to housing starts, this figure would point to a recovering U.S. economy, but it also may signal that this rebound isn't as robust as once expected.

Finally, the Michigan Consumer Sentiment Index for January dipped to a reading of 80.4 from the reading of 82.5 in December. This index combines opinions for at least 500 people each month with regard to their own near-term and long-term outlooks. With this reading falling, it's safe to assume that the opinions of consumers about the health of the economy is waning a tad.

By day's end, the S&P 500 had dipped by 7.19 points (-0.39%) to close at 1,838.70.

In spite of the second day of weakness, NII Holdings (NASDAQ:NIHD), a wireless services provider in Latin and South America, advanced 24.2% after announcing a deal with Apple (NASDAQ:AAPL) to bring the iPhone 5s and iPhone 5c to its Nextel network of customers in Brazil beginning Jan. 31. NII also forged a deal with Telefonica earlier this week to jointly develop their networks in Mexico and Brazil, so each can reach a greater number of customers. The deal is equally important to Apple, as it pushes heavily into BRIC countries with its latest smartphone. With NII pushing toward modern technology and broader network reach, it has made some very smart strategic moves this week. I still, however, can't get past the company's enormous debt load, and would strongly suggest you stick to the sidelines until it gets back to profitability and makes serious strides in reducing its debt.

Shares of genetic analysis platform designer Pacific Biosciences of California (NASDAQ:PACB) vaulted higher by 14.4% despite a lack of company-specific news... today, at least. Earlier in the week, the life sciences sector was abuzz with the introduction of a new genetic analysis tool from Illumina, which could get the job done for $1,000, signaling just how far genome analysis tools have come over the past decade. Pacific Biosciences has demonstrated a steady uptrend in its top line due to increased acceptance of its RS II Sequencing Systems. Should the company again deliver double-digit sequential quarterly-revenue growth, investors might consider pushing the company even higher. Pacific Biosciences is set to report its fourth-quarter and full-year results on Feb. 4.

Finally, Cell Therapeutics (NASDAQ:CTIC) continued its multi-week romp higher, up an additional 13.8%, following the release of its 2014 outlook and drug portfolio progress on Tuesday. Cell Therapeutics covered many of the factors we already knew, such as the clinical hold removal on tosedostat by the Food and Drug Administration, and a positive reimbursement recommendation from NICE in the U.K. in December. What really excited investors was the 2014 outlook, which includes the initiation of a second phase 3 trial for pacritinib, as well as the top-line results from the first trial, the seeking of a partner for Pixuvri outside of Western Europe, and completing enrollment for its phase 3 Opaxio study as a maintenance therapy for ovarian cancer. It's certainly going to be a busy year for Cell Therapeutics, so investors should be ready for increased volatility.

If your holdings aren't among the day's top performers, perhaps you aren't thinking far enough outside the box!
They said it couldn't be done. But David Gardner has proved them wrong, time, and time, and time again, with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently, one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market, and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of, and recommends, Apple. It also recommends Illumina and Pacific Biosciences of California. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers